The place of the protease inhibitors in antiretroviral combination therapy

Current Opinion in Infectious Diseases

Volumn 9, Issue 1, 1996, Pages 19-22

  Aboulker, Jean Pierre ^a  

^a INSERM   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR;

ANTIVIRAL ACTIVITY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; SHORT SURVEY; VIRUS INHIBITION; VIRUS REPLICATION;

EID: 0029928113     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-199602000-00005     Document Type: Short Survey

References (22)

1. ••].
2. ••].
3. ••] are major contributions to the understanding of the dynamics of HIV replication. Important implications can be drawn for the treatment of HIV infection and for its possible monitoring with the new tools of quantitative HIV RNA assays.
4. Levy JA: HIV research: a need to focus on the right target Lancet 1995, 345:1619-1621.
5. Loveday C, Kaye S, Tenant-Flowers M, Semple M, Ayliffe U, Weller IVD, Tedder RS: HIV-1 RNA serum load and resistant viral genotypes during early zldovudine therapy. Lancet 1995, 345:820-824.
6. Danner SA, Carr A, Leonard JM, Lehman LM, Gudiol F, Gonzales J, Raventos A, Rubio R, Bouza E, Pintado V, et al.: Safety, pharmacokinetics, and antiviral activity of ritonavir, an inhibitor of HIV-1 protease. Fourth International Workshop on HIV Drug Resistance. Sardinia, Italy 1995 [Abstract 75].
7. Jacobsen H, Haenggi M, Ott M, Duncan IB, Andreoni M, Vella S, Mous J: Reduced sensitivity to saquinavir: an update on genotyping from phase I/II trials. Fourth International Workshop on HIV Drug Resistance. Sardinia, Italy, July 1995 [Abstract 68].
8. Harrigan PR, Kemp SD, Kinghorn I, Bloor S, Kohli A, Clair St, Larder & the Protocol: A placebo controlled trial of AZT alone or in combination with DDI or DDC: viral load and drug resistance [Abstract]. AIDS 1994, 8(suppl 4):7.
9. 3. Second National Conference on Human Retroviruses. Washington DC 1995 [Abstract LB31].
10. Fischl MA, Stanley K, Collier AC, Arduino JM, Stein DS, Feinberg JE, Allan JD, Goldsmith JC, Powderly WG, and the NIAID AIDS Clinical Trials Group: Combination and monotherapy with zidovudine and zalcitabine in patients with advanced HIV disease. Ann Intern Med 1995, 122:24-32. The first phase III trail on combination therapy to be published. Disappointing results of the ZDV-zalcitabine combination in ZDV-exposed patients compared with the ACTG 175, Delta and NuCombo trials results.
11. 3. 35th International Conference on Antimicrobial Chemotherapy. San Francisco, USA, September 1995 [Abstract LB1].
12. Yeni P for the Delta Coordinating Committee: Preliminary results of the Delta trial. 5th European Conference on Aspects and Treatment of HIV infection. Copenhagen, Denmark, September 1995 [oral presentation].
13. Sommadossi JP, Schinazi RF, McMillan Z, Xie MY, Bryant M: A human serum glycoprotein profoundly affects antiviral activity of the protease inhibitor SC-52151 by decreasing its cellular uptake. Second National Conference on Human Retroviruses. Washington, USA, 1995 [Abstract LB4].
14. Kitchen VS, Skinner C, Ariyoshi K, Lane EA, Duncan IB, Burckhardt J, Burger HU, Bragman K, Pinching AJ, Weber JN: Safety and activity of saquinavir in HIV infection. Lancet 1995, 345:952-955.
15. Schapiro JM, Wnters M, Merigan TC: Mutational analysis of the saquinavir high dose monotherapy study. Fourth International Workshop on HIV Drug Resistance. Sardinia, Italy, July 1995 [Abstract 73].
16. Norbeck D, Hsu A, Granneman R, Denissen J, Kempf D, Molla A, Leonard J: Virologic and immunologic response to ritonavir (ABT-538), an inhibitor of HIV protease. Fourth International Workshop on HIV Drug Resistance. Sardinia, Italy, July 1995 [Abstract 70].
17. Mellors JW, McMahon DK, Chodakewitz JA, Schleif WA, Emini EA, Condra JH: Correlation between genotype evidence of HIV-1 resistance to the protease inhibitor MK-639 and loss of antiretroviral effect in treated patients. Fourth International Workshop on HIV Drug Resistance. Sardinia, Italy, July 1995 [Abstract 71].
18. Molla S, Boucher C, Korneyeva M, Gao Q, Schipper P, Lyons N, Vasavanonda S, Niu P, Stewart K, Park C, Chernyavskiy T, Kempf D, Leonard J, Norbeck D: Evolution of resistance to the protease inhibitor ritinoavir (ABT-538) in HIV infected patients. Fourth International Workshop on HIV Drug Resistance. Sardinia, Italy, July 1995 [Abstract 69].
19. Condra JH, Schleif WA, Blahy OM, Gabryelski LJ, Graham DJ, Quintero JC, Rhodes A, Robbins HL, Roth E, Shivaprakash M, et al.: In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995, 374:569-571. The paper which first described multiple- and cross-resistance in the protease inhibitor class of drugs.
20. Tisdale M, Kemp SD, Parry NR, Larder BA: Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3 thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci USA 1993, 90:5653-5656.
21. Tisdale M, Myers RE, Blair E, Kohli A, Kemp SD, Larder BA: In vitro studies support combination therapy with HIV protease inhibitors. Fourth International Workshop on HIV Drug Resistance. Sardinia, Italy, July 1995 [Abstract 61].
22. Richmann DD: Protease uninhibited. Nature 1995, 374:494. A short but enlightening discussion about the selection of mutant variants by active HIV inhibitors and how to exploit cumulative mutations to select better treatments and design new drug derivatives.